Some experimental attempts were made to evaluate the role of the inhibition of the renin-angiotensin system (particularly losartan) in the treatment of liver fibrosis, with promising results in small studies involving patients with MASLD-related liver fibrosis [208] or in a group of liver-transplanted patients with post-transplant risk of recurrence of HCV-related liver disease (even if the risk of this complication has been widely reduced nowadays by the introduction of direct acting antivirals that avoid the recurrence of HCV infection on the transplanted liver) [209]. Here, REN is linked to Hepatic fibrosis.